ArticleClinical ophthalmology (Auckland, N.Z.)2026
Geometry-Based Intravitreal Pharmacokinetics: A Theoretical Pharmacokinetic Modeling Study Using Triamcinolone Acetonide and Vancomycin as Representative Intravitreal Agents.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To quantify how anatomical variation in vitreous cavity volume, estimated from axial length (AL) using the VIVEX formula, influences intravitreal drug concentration, therapeutic exposure duration, and immediate intraocular pressure (IOP) dynamics under fixed-dose intravitreal therapy. Patients and Methods: This theoretical pharmacokinetic modeling study utilized the VIVEX equation {V = (π/6) × AL Results: Modeled VV increased from 2.98 mL (AL 20 mm) to 11.76 mL (AL 30 mm), producing an approximately fourfold difference in C Conclusion: Anatomical differences in VV substantially and predictably influence intravitreal pharmacokinetics. The modeled results demonstrate that fixed intravitreal dosing leads to substantial geometry-driven differences in drug exposure across eye sizes. Fixed dosing strategies may increase peak exposure and IOP load in small eyes and shorten effective therapeutic duration in large myopic eyes. Biometry-stratified clinical studies are warranted to validate these modeling predictions and to assess their clinical relevance in intravitreal antibiotic and corticosteroid therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.